Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Jiangxi Synergy Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic and specialty pharmaceuticals, primarily serving the Chinese market. The company distinguishes itself through its focus on high-quality production processes and a diverse product portfolio, including oncology and cardiovascular drugs, which are critical in addressing significant health challenges in China.
Jiangxi Synergy generates revenue through the sale of generic and specialty drugs, leveraging its established relationships with hospitals and pharmacies across China. The company benefits from pricing power due to its reputation for quality and compliance with stringent regulatory standards, which is crucial in the highly competitive pharmaceutical landscape.
Regulatory approvals for new drug formulations
Market share changes in the oncology segment
Pricing pressure from competitors in the generic market
Partnerships or collaborations with larger pharmaceutical firms
Regulatory changes affecting drug approval processes
Intense competition leading to price erosion in the generic drug market
Emergence of new competitors in the specialty drug space
Potential for larger pharmaceutical companies to enter the generic market
Low return on equity (3.0%) indicating potential inefficiencies in capital utilization
Negative free cash flow could limit operational flexibility
moderate - As a healthcare provider, demand for pharmaceuticals is somewhat insulated from economic downturns, but overall spending can be affected by GDP growth and consumer confidence.
Interest rates impact the company's cost of capital for financing R&D and expansion. Higher rates could increase borrowing costs, potentially affecting profitability and investment in new projects.
minimal - The company maintains a low debt-to-equity ratio of 0.30, indicating limited reliance on external financing.
value - Investors may be drawn to the company's low valuation metrics, particularly its price-to-book ratio of 1.2x.
moderate - The stock has experienced significant fluctuations, with a 1-year return of -17.1%, indicating potential volatility.
